Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy

PACE - Pacing and Clinical Electrophysiology

Volumn 28, Issue 4, 2005, Pages 295-300

  Lawrenz, Thorsten ^a   Obergassel, Ludger ^a   Lieder, Frank ^a   Leuner, Christian ^a   Strunk Mueller, Claudia ^a   Meyer Zu Vilsendorf, Dorothee ^a   Beer, Gerald ^a   Kuhn, Horst ^a  

^a OWL University   (Germany)

Author keywords

Alcohol septal ablation; Hypertrophic cardiomyopathy; ICD; Prognosis; TASH; Ventricular fibrillation

Indexed keywords

ADULT; ARTICLE; CATHETER ABLATION; CLINICAL ARTICLE; DEFIBRILLATOR; DEVICE; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART ARREST; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; PRIMARY PREVENTION; RESUSCITATION; SECONDARY PREVENTION; SUDDEN DEATH; SYMPTOM; SYNCOPE; TRANSCORONARY ABLATION OF SEPTAL HYPERTROPHY; TREATMENT INDICATION;

AGED; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART SEPTUM; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 18044398067     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2005.09327.x     Document Type: Article

References (31)

1. Kuhn H. Transcoronare Ablation der Septum-Hypertrophic (TASH) Bericht über das 1. Bielefelder Werkstattgespräch. Z Kardiol 1997; 87:244-248.
2. Kuhn H, Gietzen F, Leuner C, et al. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 1997; 18:846-851.
3. Kuhn H, Gietzen F, Schäfers M, et al. Changes in the left ventricular outflow tract after transcoronary ablation of the septal hypertrophy for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and measuring the myocardial glucose utilisation and perfusion. Eur Heart J 1999; 20:1808-1817.
4. Gietzen F, Leuner C, Gerenkamp T, et al. Abnahme der Obstruktion bei hypertrophischer Kardiomyopathie während passagerer Okklusion des ersten Septalastes der linken Koronararterie (abstract). Z Kardiol 1994; 83(146).
5. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346:211-214.
6. Gietzen FH, Leuner CJ, Raute-Keinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999; 20:1342-1354.
7. Kuhn H. Transcoronary ablation of septal hypertrophy (TASH): A new treatment option for hypertrophic obstructive cardiomyopathy (abstract). Z Kardiol 2000; 89:IV41-IV54.
8. Kuhn H. Transcoronary ablation of septal hypertrophy (TASH): A 5-year experience. Z Kardiol 2000; 89:559-564.
9. Lakkis NM, Nagueh SF, Dunn JK, et al. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000; 36:852-855.
10. Lakkis N. New treatment methods for patients with hypertrophic obstructive cardiomyopathy. Curr Opin Cardiol 2000; 15:172-177.
11. Nagueh SF, Lakkis NM, Middelton KJ, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999; 99:344-347.
12. Seggewiss H, Gleichmann U, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998; 31:252-258.
13. Seggewiss H, Faber L, Ziemssen P, et al. One-year follow-up after echocardiographically-guided percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Dtsch Med Wochenschr 2001; 126:424-430.
14. Faber L, Meissner A, Ziemssen O, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Long term follow up of the first series of 25 patients. Heart 2000; 83:326-331.
15. Maron BJ, Roberts WC, Edwards JE, et al. Sudden death, in patients with hypertrophic cardiomyopathy: Characterization of 26 patients with functional limitation. Am J Cardiol 1978; 41:803-810.
16. Maron BJ, Roberts WC, Epstein SE, et al. Sudden death in hypertrophic cardiomyopathy: A profile of 78 patients. Circulation 1982; 65:1388-1394.
17. Maron BJ. Ventricular arrhythmias, sudden death, and prevention in patients with hypertrophic cardiomyopathy. Curr Cardiol Rep 2000; 2:522-528.
18. McKenna WJ, Chetty S, Oakley CM, et al. Arrhythmia in hypertrophic cardiomyopathy: Exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol 1980; 45:1-5.
19. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342:1778-1785.
20. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33:1596-1601.
21. McKenna WJ, Franklin RC, Nihoyannopoulos P, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11:147-153.
22. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342:365-373.
23. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: Role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998; 31:1081-1085.
24. Silka MJ, Kron J, Dunnigan A, et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation 1993; 87:800-807.
25. Tripodi D, McAreavey D, Epstein ND, et al. Impact of the implantable defibrillator in hypertrophic cardiomyopathy patients at high risk for sudden death. J Am Coll Cardiol 1993; 21:352A.
26. Borggrefe M, Breithardt G. Is the implantable defibrillator indicated in patients with hypertrophic cardiomyopathy and aborted sudden death? J Am Coll Cardiol 1998; 31:1086-1088.
27. Lawrenz T, Gietzen F, Lieder F, et al. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transcoronary ablation of the septal hypertrophy (TASH) (abstract). Eur Heart J 2002; 734.
28. Maron MS, Olivotto S, Betocchi SA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348:295-303.
29. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 2000; 5:425-426.
30. Obergassel L, Gietzen FH, Strunk-Mueller C, et al. Does transcoronary ablation of septal hypertrophy (TASH) in hypertrophic cardiomyopathy (HOCM) induce an arrhythmogenic substrate? Clinical results and holter-ECG-Data (abstract). PACE 2001; 24:694.
31. Gietzen FM, Bartelsmeier M, Lawrenz T, et al. Transcoronary ablation of the septal hypertrophy for HOCM. No evidence for the induction of an arrhythmogenic substrate (abstract). Eur Heart J 2002; 4:533.